{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-24-000003","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.346229+00:00","generated_at":"2026-06-06T13:48:57.733708+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allogene amends Notch collaboration, retains exclusive rights to one CAR target, gives up others","bullets":["Relinquished exclusive rights to all original CAR targets except one; option limited to one additional target.","If Notch out-licenses Released Targets, Allogene receives percentage of upfront/milestone payments up to a cap and low single-digit royalties.","Allogene made ~$22.7M total equity investments in Notch ($5M seed, $15.9M Series A, $1.8M common) and holds ~23% voting interest.","Amended Agreement includes anti-dilution protections for Allogene's stake in Notch for certain pre-IPO equity financings."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-24-000003","json":"https://secwatch.observer/filing/0001737287-24-000003.json","markdown":"https://secwatch.observer/filing/0001737287-24-000003.md","text":"https://secwatch.observer/filing/0001737287-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/0001737287-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/allo-20240125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T13:48:57.733708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"856044168736ebbec85029251694f40a613a72f9","claim":"Allogene Therapeutics, Inc. amended Amended and Restated Collaboration and License Agreement with Notch Therapeutics, Inc. valued at Amended and restated collaboration and license agreement; company relinquished exclusive rights to o (effective 2024-01-25).","evidence_excerpt":"On January 25, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Collaboration and License Agreement (the “Amended Agreement”) with Notch Therapeutics, Inc. (“Notch”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/0001737287-24-000003-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Notch Therapeutics, Inc."},{"label":"Value","value":"Amended and restated collaboration and license agreement; company relinquished exclusive rights to o"},{"label":"Effective","value":"2024-01-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}